Trial Outcomes & Findings for The Effects of Rimonabant, on Weight and Metabolic Risk Factors (NCT NCT00547118)

NCT ID: NCT00547118

Last Updated: 2019-11-04

Results Overview

The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from "1=Not Present" to "7=Very Severe". Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

17 participants

Primary outcome timeframe

Baseline (Week 0) and end of study (Week 16)

Results posted on

2019-11-04

Participant Flow

18 participants signed consent for the study. 1 participant was withdrawn prior to randomization, 2 participants (one from each group) withdrawn after randomization but prior to drug initiation. n=15 participants included in data analysis for aims 1, 2, 8, 9, 10, and n=14 analyzed for aims 3-7 due withdrawal prior to EOS neruopsych testing.

Participant milestones

Participant milestones
Measure
Rimonabant
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
Placebo
Placebo Placebo: Placebo
Overall Study
STARTED
8
9
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
8
9

Reasons for withdrawal

Reasons for withdrawal
Measure
Rimonabant
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
Placebo
Placebo Placebo: Placebo
Overall Study
Did not qualify prior to starting drug
1
1
Overall Study
Study suspended
7
8

Baseline Characteristics

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Rimonabant
n=7 Participants
Rimonabant Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo Placebo: Placebo
Total
n=15 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
n=99 Participants
8 Participants
n=107 Participants
15 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Continuous
45.9 Years
STANDARD_DEVIATION 6.9 • n=99 Participants
42.4 Years
STANDARD_DEVIATION 13.3 • n=107 Participants
45.7 Years
STANDARD_DEVIATION 8.4 • n=206 Participants
Sex: Female, Male
Female
2 Participants
n=99 Participants
4 Participants
n=107 Participants
6 Participants
n=206 Participants
Sex: Female, Male
Male
5 Participants
n=99 Participants
4 Participants
n=107 Participants
9 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=99 Participants
5 Participants
n=107 Participants
8 Participants
n=206 Participants
Race (NIH/OMB)
White
4 Participants
n=99 Participants
3 Participants
n=107 Participants
7 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
7 participants
n=99 Participants
8 participants
n=107 Participants
15 participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from "1=Not Present" to "7=Very Severe". Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Brief Psychiatric Rating Scale (BPRS) Total Score
Week 0
33.5 units on a scale
Standard Deviation 7.5
34.5 units on a scale
Standard Deviation 4.6
Brief Psychiatric Rating Scale (BPRS) Total Score
Week 16
32.8 units on a scale
Standard Deviation 3.9
33.6 units on a scale
Standard Deviation 6.2

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from "1=Not Present" to "7=Very Severe". The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Brief Psychiatric Rating Scale (BPRS) Psychosis Score
Week 0
9.4 units on a scale
Standard Deviation 4.3
11.4 units on a scale
Standard Deviation 3.4
Brief Psychiatric Rating Scale (BPRS) Psychosis Score
Week 16
7.6 units on a scale
Standard Deviation 3.0
8.6 units on a scale
Standard Deviation 3.4

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).

The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 0
85.0 units on a scale
Standard Deviation 19.8
78.3 units on a scale
Standard Deviation 10.2
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 16
83.0 units on a scale
Standard Deviation 11.8
84.3 units on a scale
Standard Deviation 12.6

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).

The Iowa Gambling Task (IGT) is a computer-administered cognitive test that assesses risk preferences by simulating real-life decision making using uncertainty, rewards, and penalties. In the task, players are given four decks of cards and an endowment of fake money (e.g., $2000). Players are instructed to select cards one at a time and try to lose the least amount of money and win the most. The outcome measure was the number of rewarded minus punished card choices. Task has a maximum of 100 trials. The net score is the difference between the number of choices from advantageous decks verses disadvantageous decks. Higher scores are better and can range from -50 to +50.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
The Iowa Gambling Task (IGT)
Week 0
5.1 units on a scale
Standard Deviation 19.8
1.3 units on a scale
Standard Deviation 22.7
The Iowa Gambling Task (IGT)
Week 16
-0.3 units on a scale
Standard Deviation 25.2
-9.0 units on a scale
Standard Deviation 29.7

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).

The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
N-Back Neurocognitive Task: 0-back Condition
Week 0
3.8 units on a scale
Standard Deviation 0.5
3.6 units on a scale
Standard Deviation 0.6
N-Back Neurocognitive Task: 0-back Condition
Week 16
3.9 units on a scale
Standard Deviation 0.6
3.6 units on a scale
Standard Deviation 0.4

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).

The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
N-Back Neurocognitive Task: 1-back Condition
Week 0
3.2 units on a scale
Standard Deviation 0.8
3.2 units on a scale
Standard Deviation 0.6
N-Back Neurocognitive Task: 1-back Condition
Week 16
3.3 units on a scale
Standard Deviation 0.7
2.8 units on a scale
Standard Deviation 0.2

PRIMARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).

The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
N-Back Neurocognitive Task: 2-back Condition
Week 0
1.5 units on a scale
Standard Deviation 0.6
1.6 units on a scale
Standard Deviation 0.6
N-Back Neurocognitive Task: 2-back Condition
Week 16
1.5 units on a scale
Standard Deviation 0.4
1.6 units on a scale
Standard Deviation 0.4

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Schedule for Assessment of Negative Symptoms (SANS) Total Score
Week 0
28.7 units on a scale
Standard Deviation 10.9
26.7 units on a scale
Standard Deviation 15.5
Schedule for Assessment of Negative Symptoms (SANS) Total Score
Week 16
33.2 units on a scale
Standard Deviation 11.6
32.4 units on a scale
Standard Deviation 15.8

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

SANS Global Anhedonia score. Scores can range from 0-5, with higher scores indicating more severe anhedonia.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Schedule for Assessment of Negative Symptoms (SANS) - Anhedonia
Week 0
1.9 units on a scale
Standard Deviation 1.0
1.6 units on a scale
Standard Deviation 0.9
Schedule for Assessment of Negative Symptoms (SANS) - Anhedonia
Week 16
1.9 units on a scale
Standard Deviation 1.0
1.9 units on a scale
Standard Deviation 1.1

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

SANS Global Rating of Affective Flattening. Scores can range from 0-5, with higher scores indicating more severe blunted affect.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Schedule for Assessment of Negative Symptoms (SANS) - Blunted Affect
Week 0
1.3 units on a scale
Standard Deviation 0.9
1.1 units on a scale
Standard Deviation 1.0
Schedule for Assessment of Negative Symptoms (SANS) - Blunted Affect
Week 16
1.8 units on a scale
Standard Deviation 0.9
1.2 units on a scale
Standard Deviation 1.0

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

SANS Global Rating of Alogia. Scores can range from 0-5, with higher scores indicating more severe alogia.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Schedule for Assessment of Negative Symptoms (SANS) - Alogia
Week 0
0.5 units on a scale
Standard Deviation 0.5
0.9 units on a scale
Standard Deviation 1.4
Schedule for Assessment of Negative Symptoms (SANS) - Alogia
Week 16
0.9 units on a scale
Standard Deviation 1.1
1.4 units on a scale
Standard Deviation 1.3

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

SANS Avolition score. Scores can range from 0-5, with higher scores indicating more severe avolition.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Schedule for Assessment of Negative Symptoms (SANS) - Avolition
Week 0
2.6 units on a scale
Standard Deviation 1.1
2.4 units on a scale
Standard Deviation 1.1
Schedule for Assessment of Negative Symptoms (SANS) - Avolition
Week 16
2.6 units on a scale
Standard Deviation 1.2
3.0 units on a scale
Standard Deviation 1.2

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

The global improvement score can range from 1-7, with higher scores indicating worse total improvement clinically.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Clinical Global Impression (CGI)
Week 16
4.2 units on a scale
Standard Deviation 0.4
4.0 units on a scale
Standard Deviation 1.0
Clinical Global Impression (CGI)
Week 0
4.2 units on a scale
Standard Deviation 0.4
4.2 units on a scale
Standard Deviation 0.7

SECONDARY outcome

Timeframe: Baseline (Week 0) and end of study (Week 16)

Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.

The CDS total score is the addition of scores from items 1-9. Each item's scores range on a scale of "0=Absent" to "3=Severe". The total score range is from 0-27. Higher total scores indicate a more severe depression rating.

Outcome measures

Outcome measures
Measure
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
Calgary Depression Scale (CDS) Total Score
Week 0
3.0 units on a scale
Standard Deviation 2.2
3.0 units on a scale
Standard Deviation 2.4
Calgary Depression Scale (CDS) Total Score
Week 16
2.0 units on a scale
Standard Deviation 2.5
2.0 units on a scale
Standard Deviation 2.7

Adverse Events

Rimonabant

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Rimonabant
n=8 participants at risk
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
Placebo
n=9 participants at risk
Placebo Placebo: Placebo
General disorders
Headache
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
55.6%
5/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Renal and urinary disorders
Enuresis
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Metabolism and nutrition disorders
Anorexia
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
33.3%
3/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Respiratory, thoracic and mediastinal disorders
Sedation
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Gastrointestinal disorders
Abdominal pain
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Metabolism and nutrition disorders
weight loss
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
General disorders
malaise
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
33.3%
3/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Ear and labyrinth disorders
tinnitus
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
Gastrointestinal disorders
nausea
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
General disorders
dizziness
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
General disorders
dry mouth
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
General disorders
insomnia
12.5%
1/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
33.3%
3/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
General disorders
vomiting
12.5%
1/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
11.1%
1/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used

Additional Information

Dr. Robert W. Buchanan

Maryland Psychiatric Research Center

Phone: 410-402-7876

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place